Clinical trials: Telangiectases
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Macular Telangiectasia
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Idiopathic juxtafoveal telangiectasia type 1 is a rare unilateral disease that mostly affects men before 50 years of age. Mac Tel 1 are characterized by microvascular telangiectasia and increased tortuosity of the macular…
- Trial name
- TELeMAC (NCT03845049)
- Testing
- Inclusion examinations, Aflibercept Injection [Eylea], Examinations during study (every month)
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hereditary Hemorrhagic Telangiectasia
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research.
- Trial name
- BVMC6203 (NCT01158807)
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 2,272 people
- Sponsor
- Unity Health Toronto
Ataxia Telangiectasia, Growth Failure
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT).
- Trial name
- GHAT (NCT01052623)
- Testing
- Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hereditary Hemorrhagic Telangiectasia
Ultra-low-dose Chest CT for HHT
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the…
- Trial name
- NCT04874558
- Testing
- Ultra-low dose chest CT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment.
- Trial name
- EPERO (NCT04113187)
- Testing
- Propranolol treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Bordeaux
Hereditary Hemorrhagic Telangiectasia
Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia
Hereditary haemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic disease associated with mutations in genes encoding proteins of the transforming growth factor β (TGF-β) family, i.e.
- Trial name
- CARDI-HHT (NCT07101575)
- Testing
- Transthoracic echocardiography
- Volunteers
- 380 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Telangiectasia
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT.
- Trial name
- NCT00378196
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Hereditary Haemorrhagic Telangiectasia
Vitamin D and Hereditary Haemorrhagic Telangiectasia
The study aims to assess whether supplementing vitamin D in patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT) will decrease the frequency and severity of nosebleeds these patients experience.
- Trial name
- NCT03981562
- Testing
- Vit D
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- St. Paul's Hospital, Canada
Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
This study will investigate the effectiveness of oral low-dose tacrolimus for the treatment of recurrent nasal hemorrhage in HHT subjects.
- Trial name
- NCT04646356
- Testing
- Tacrolimus capsule (low-dose)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Hereditary Hemorrhagic Telangiectasia
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial.
- Trial name
- NCT00375622
- Testing
- Tamoxifen
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Hereditary Hemorrhagic Telangiectasia (HHT)
Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NCT01402531
- Testing
- Submucosal Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Hereditary Haemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformation
Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT)
Computed tomography (CT) is the modality of choice to characterize pulmonary arteriovenous malformations (PAVMs) in patients with hereditary haemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Haemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformation, Cerebral Disorder
- Trial name
- PAVM (NCT03940014)
- Testing
- Data collection from standard follow up
- Volunteers
- 170 people
- Sponsor
- Hospices Civils de Lyon
Solid Tumor
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
This is a single sequence 2-period open label study in participants with advanced solid tumors. The purpose of Period 1 of this study is to assess the mass balance to determine drug-related entities present in circulation and…
- Trial name
- NCT06308263
- Testing
- Tuvusertib [14C]Tuvusertib microtracer, Tuvusertib, Tuvusertib + [14C]Tuvusertib microdose bolus injection
- Where
- Hungary
- Volunteers
- 12 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Hereditary Hemorrhagic Telangiectasia (HHT), Obstructive Sleep Apnea (OSA)
Prevalence of Obstructive Sleep Apnea in HHT and HHT-specific Challenges in OSA-therapy - a Retrospective Cohort Study
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder (prevalence approx. 1:5,000-1:8,000) characterized by recurrent epistaxis, mucocutaneous telangiectasias and visceral vascular malformations.
- Trial name
- NCT07886632
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Essen
Breast Cancer, Radiation-Induced Telangiectasias
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
The purpose of this study is to see how the look of telangiectasias (small dilated blood vessels) on radiated breast skin when altered by the pulsed dye laser affects a patient's overall well being.
- Trial name
- NCT01803516
- Testing
- questionnaires
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hemorrhagic Hereditary Telangiectasia
Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study
The efficacy of anti-VEGF treatments such as Bevacizumab in cases of HHT can be considered because of the molecular mechanisms implied in angiogenesis and HHT, as well as the mechanisms of action of this type of treatment.
- Trial name
- METAFORE (NCT00843440)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Leg Veins
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
The primary objective is to compare physician-assessed clearance of telangiectatic veins between treatment legs using the Physician Global Aesthetic Improvement Scale (PGAIS).
- Trial name
- NCT07342413
- Testing
- Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine, Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Telangiectasis, Erythema
Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness
The purpose of the study is to compare efficacy and adverse effects of pulsed dye laser and intense pulsed light in patients with skin telangiectasia and redness.
- Trial name
- NCT00206921
- Testing
- Pulsed dye laser, Intense pulsed light
- Where
- Denmark
- Sponsor
- Bispebjerg Hospital